tirzepatide in type 1 diabetes The evidence for GLP-1 receptor agonists is no longer sparse. It is growing — and it is specific.ADJUST-T1D. TIRTLE1. Two years of real-world data. Meta-analyses pooling hundreds of EASD 2025: Tirzepatide Shows Early

Pramono, A., Jocken, J

Lilly, BI and Jardiance may trigger one in diabetes Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV events In a first for diabetes, Lilly and Boehringer's Jardiance prevents heart attacks, strokes in trial FDA warning on J&J's Invokana adds more complexities to diabetes drug battles

The US telehealth company confirmed today that it is launching an oral version of GLP-1 agonist semaglutide the active ingredient in Wegovy at a knockdown introductory price of $49 per month with a five-month plan

Employers should be aware, however, that Medicare-eligible employees (including those on COBRA, retirees, or older workers) may have questions about the program, so employers should be prepared to direct them to the appropriate resources for guidance

The other needs just one shot per week